From Nasdaq:

Apellis Pharmaceuticals, Inc. (APLS) shares surged 14.7% to $68.35 due to strong preliminary net product revenues in the United States. Marketed drugs Empaveli and Syfovre contributed to the impressive revenue numbers. APLS is expected to post a $0.88 loss per share in its upcoming report, with revenues expected to reach $121.62 million.

Market researchers believe that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. For APLS, the consensus EPS estimate for the quarter has been revised 8.7% higher over the last 30 days to the current level, translating into potential price appreciation.

Nurix Therapeutics, Inc. ended 0.9% higher at $9.96 in the last trading session. For its upcoming report, the consensus EPS estimate has remained unchanged over the past month at -$0.51, with NRIX currently holding a Zacks Rank of #2 (Buy).

Zacks expert-recommended 5 potential stocks to reach +100% or more. Most of these stocks are under Wall Street radar, providing an opportunity to enter at the initial stage. Download free Zacks report for the latest stock recommendations or to get comprehensive stock analysis.



Read more: Apellis Pharmaceuticals, Inc. (APLS) Soars 14.7%: Is Further Upside Left in the Stock?